Different expression of calgizzarin (S100A11) in normal colonic epithelium, adenoma and colorectal carcinoma.

The aim of the study was to detect proteomic markers usable to distinguish colorectal carcinoma from colon adenoma for a better understanding of the molecular mechanisms in the process of tumourigenesis. Therefore, we microdissected colon carcinoma tissue, epithelial colon adenoma tissue as well as normal adjacent colon epithelium and determined protein profiles by SELDI-TOF MS. A multitude of significantly different signals was detected. For their identification colon biopsis were lysed and subjected to a two-dimensional gel electrophoresis for separation. Subsequently, we identified nearly 100 proteins by tryptic digestion, peptide fingerprint mapping and database search. Calgizzarin (S100A11; S100C) identified by peptide fingerprint mapping correlated very well with a significantly differentially expressed signal found in prior protein profiling. Using an immunodepletion assay we confirmed the identity of this signal as calgizzarin. To localise calgizzarin in tissues we performed immunohistochemistry. For further confirmation of the identity of calgizzarin we re-analysed IHC-positive as well as IHC-negative tissue sections on ProteinChip arrays. This work demonstrates that biomarkers in colorectal cancer can be detected, identified and assessed by a proteomic approach comprising tissue-microdissection, protein profiling and immunological techniques.

[1]  K. Yoshimoto,et al.  Human calgizzarin; one colorectal cancer-related gene selected by a large scale random cDNA sequencing and northern blot analysis. , 1995, Cancer letters.

[2]  D. Driesch,et al.  Proteomic profiling in microdissected hepatocellular carcinoma tissue using ProteinChip technology. , 2004, International journal of oncology.

[3]  U. Settmacher,et al.  Discovery and identification of alpha-defensins as low abundant, tumor-derived serum markers in colorectal cancer. , 2005, Gastroenterology.

[4]  S. Weinberger,et al.  Current developments in SELDI affinity technology. , 2004, Mass spectrometry reviews.

[5]  Claus W Heizmann,et al.  S100 proteins: structure, functions and pathology. , 2002, Frontiers in bioscience : a journal and virtual library.

[6]  R. Banks,et al.  Laser capture microdissection and proteomics: Possibilities and limitation , 2001, Proteomics.

[7]  A. Wellmann,et al.  ProteinChip Array analysis of microdissected colorectal carcinoma and associated tumor stroma shows specific protein bands in the 3.4 to 3.6 kDa range. , 2004, Anticancer research.

[8]  M. Gleave,et al.  Protein Profiling of Microdissected Prostate Tissue Links Growth Differentiation Factor 15 to Prostate Carcinogenesis , 2004, Cancer Research.

[9]  C. Heizmann,et al.  The S100 family of EF-hand calcium-binding proteins: functions and pathology. , 1996, Trends in biochemical sciences.

[10]  P. Chaurand,et al.  Profiling proteins from azoxymethane‐induced colon tumors at the molecular level by matrix‐assisted laser desorption/ionization mass spectrometry , 2001, Proteomics.

[11]  M. Sakaguchi,et al.  Relationship between Contact Inhibition and Intranuclear S100c of Normal Human Fibroblasts , 2000, The Journal of cell biology.

[12]  J. Issa,et al.  Epigenetic changes in colorectal cancer , 2004, Cancer and Metastasis Reviews.

[13]  Naoto Tsuchiya,et al.  Up-regulation of hnRNP A1 gene in sporadic human colorectal cancers. , 2005, International journal of oncology.

[14]  W. Seeger,et al.  BMC Biotechnology BioMed Central Methodology article A gene expression system offering multiple levels of regulation: the Dual Drug Control (DDC) system , 2004 .

[15]  Nirag Jhala,et al.  Diagnostic Markers That Distinguish Colon and Ovarian Adenocarcinomas: Identification by Genomic, Proteomic, and Tissue Array Profiling , 2004 .

[16]  K. Pritzker,et al.  Cancer biomarkers: easier said than done. , 2002, Clinical chemistry.

[17]  Henrik Lindberg,et al.  Transforming Growth Factor-β1 Specifically Induce Proteins Involved in the Myofibroblast Contractile Apparatus* , 2004, Molecular & Cellular Proteomics.

[18]  H. Davies,et al.  Tissue-specific microdissection coupled with ProteinChip array technologies: applications in cancer research. , 2000, BioTechniques.

[19]  S. Gammeltoft,et al.  Upregulated expression of human neutrophil peptides 1, 2 and 3 (HNP 1-3) in colon cancer serum and tumours: a biomarker study , 2005, BMC Cancer.

[20]  B. Aronow,et al.  Transcriptional profiles of intestinal tumors in Apc(Min) mice are unique from those of embryonic intestine and identify novel gene targets dysregulated in human colorectal tumors. , 2005, Cancer research.

[21]  Bert Vogelstein,et al.  Mutations of mitotic checkpoint genes in human cancers , 1998, Nature.

[22]  F. von Eggeling,et al.  Biomarker Discovery and Identification in Laser Microdissected Head and Neck Squamous Cell Carcinoma with ProteinChip® Technology, Two-dimensional Gel Electrophoresis, Tandem Mass Spectrometry, and Immunohistochemistry* , 2003, Molecular & Cellular Proteomics.

[23]  D. Parkin,et al.  Global cancer statistics in the year 2000. , 2001, The Lancet. Oncology.

[24]  Günther Ernst,et al.  A Technical Triade for Proteomic Identification and Characterization of Cancer Biomarkers , 2004, Cancer Research.

[25]  Jiří Knížek,et al.  Protein abundance alterations in matched sets of macroscopically normal colon mucosa and colorectal carcinoma , 1999, Electrophoresis.

[26]  C. Heizmann,et al.  S100 proteins: structure, functions and pathology. , 2002, Frontiers in bioscience : a journal and virtual library.

[27]  F. von Eggeling,et al.  Identification of proteins from colorectal cancer tissue by two-dimensional gel electrophoresis and SELDI mass spectrometry. , 2005, International journal of molecular medicine.